# Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda

Source: https://onco.cc/institutions/niguarda-cancer-center/  
OnCo record `niguarda-cancer-center` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Milan's largest public hospital, whose cancer centre under Salvatore Siena and Andrea Sartore-Bianchi ran HERACLES, the trial that proved HER2 is a target in bowel cancer.

## Summary

The Niguarda Cancer Center is the oncology department of Milan's Niguarda hospital, a large public teaching hospital of the University of Milan. Under Salvatore Siena it built a programme in molecular oncology of colorectal cancer, running HERACLES, the first trial to show that HER2-directed therapy works in HER2-amplified colorectal cancer, contributing to the panitumumab trials that established RAS testing, and hosting the phase 1 unit that led DESTINY-CRC01. Andrea Sartore-Bianchi directs its clinical research and precision oncology programme.

## Fields

- Kind: Institution
- Last checked: 2026-09-18
- Also known as: Ospedale Niguarda; Niguarda Ca' Granda Hospital; Falck Division of Medical Oncology
- City: Milan, IT
- Type: hospital
- Website: https://www.ospedaleniguarda.it

## Sources

- Ospedale Niguarda: https://www.ospedaleniguarda.it

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- trials: [HERACLES](https://onco.cc/trials/heracles/)
- people: [Andrea Sartore-Bianchi](https://onco.cc/people/andrea-sartore-bianchi/), [Salvatore Siena](https://onco.cc/people/salvatore-siena/)
- key papers: [Assessment of a HER2 scoring system for colorectal cancer: results from a validation study](https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/), [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)](https://onco.cc/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/), [Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer](https://onco.cc/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/)

---
JSON: https://onco.cc/api/v1/entities/niguarda-cancer-center.json